For this study, Tregs from healthy individuals were chosen in order to examine the effect of MSCs from OA patients on functional T lymphocytes. However, as

stated above, it is necessary to conduct further research on how MSCs and Tregs taken from the same patients interact. In our experiments, blood volumes up to 150 ml were necessary to isolate a sufficient number of Tregs to conduct the co-culture experiments. While this is unproblematic for healthy individuals, in the context of a perioperative setting of a total hip arthroplasty with its high blood loss these volumes were considered too important to be taken from the OA patients. We are currently working on optimizing the isolation procedures as well as on methods that can provide Tregs from I BET 762 OA patients without taking

important blood samples, such as collecting cells during the intraoperative autotransfusion procedure. This study addressed only changes in phenotypical Treg properties and its important activation marker FoxP3. Our experiments cannot provide information on functional changes in Treg suppression potency. These experiments will need to be carried out in future to determine whether MSC immunomodulation has an effect on the functional properties of Tregs. Joint inflammation may have differed among the patients recruited in this study; whether this has an effect on MSC Afatinib molecular weight immunomodulatory processes in vitro will need to be determined in future experiments. Therefore, it may be necessary to correlate inflammation in the synovium with the in-vitro immunomodulatory properties of MSCs. We were able to detect IL-6 as an important factor in MSC–Treg interaction; however, future studies should focus upon other possible cytokines involved. We would like to acknowledge Patrick Göthlich, Marc Hoffmann and Elena Tripel for their support. The study was carried out with internal funding by the Forschungsfond Orthopädische Universitätsklinik (F.200086). None of the authors received external funding in connection with the study presented in this publication.

The authors declare that they have no competing interests. “
“Modified vaccinia Ankara-expressing Ag85A (MVA85A) is a new tuberculosis (TB) vaccine aimed at enhancing immunity induced by BCG. We investigated the safety and immunogenicity of MVA85A tuclazepam in healthy adolescents and children from a TB endemic region, who received BCG at birth. Twelve adolescents and 24 children were vaccinated and followed up for 12 or 6 months, respectively. Adverse events were documented and vaccine-induced immune responses assessed by IFN-γ ELISpot and intracellular cytokine staining. The vaccine was well tolerated and there were no vaccine-related serious adverse events. MVA85A induced potent and durable T-cell responses. Multiple CD4+ T-cell subsets, based on expression of IFN-γ, TNF-α, IL-2, IL-17 and GM-CSF, were induced.